Table 2.
Univariate and multivariate analysis of overall survival prior to match
| Variable | Univariate | Multivariate | ||
|---|---|---|---|---|
| HR (95% CI) | p-value | HR (95% CI) | p-value | |
| Sex, male | 1.1 (0.9, 1.3) | 0.410 | ||
| ALB, g/L | 1.0 (1.0, 1.0) | 0.005 | 1.0 (1.0, 1.0) | 0.013 |
| Liver fibrosis | ||||
| No significant fibrosis | Ref | Ref | ||
| Significant fibrosis | 1.4 (1.0, 2.0) | 0.064 | 1.7 (1.2, 2.6) | 0.008 |
| Advanced fibrosis | 1.7 (1.2, 2.4) | 0.002 | 2.1 (1.4, 3.1) | <0.001 |
| Liver cirrhosis | 1.5 (1.0, 2.2) | 0.036 | 1.4 (0.9, 2.2) | 0.124 |
| Tumor size, >5 cm | 1.7 (1.4, 2.0) | <0.001 | 1.3 (1.0, 1.6) | 0.034 |
| Tumor number, ≥2 | 1.2 (1.0, 1.4) | 0.019 | 1.0 (0.7, 1.3) | 0.825 |
| Satellite lesions, absent | 0.7 (0.6, 0.8) | <0.001 | 0.8 (0.6, 1.1) | 0.203 |
| Tumor thrombus, absent | 0.7 (0.6, 0.8) | <0.001 | 0.8 (0.6, 1.0) | 0.080 |
| Lymph node infiltration | ||||
| Present | Ref | Ref | ||
| Absent | 2.0 (1.67, 2.5) | <0.001 | 2.5 (1.1, 5.0) | 0.021 |
| Differentiation | ||||
| Well | Ref | Ref | ||
| Moderate | 2.9 (1.1, 7.7) | 0.037 | 3.4 (1.1, 10.7) | 0.039 |
| Poor | 5.6 (2.1, 14.9) | <0.001 | 5.8 (1.8, 18.3) | 0.003 |
| Undifferentiated | 19.7 (6.7, 58.0) | <0.001 | 22.8 (6.4, 81.6) | <0.001 |
| 8th AJCC stage | ||||
| I | Ref | Ref | ||
| II | 0.8 (0.6, 1.1) | 0.172 | 0.6 (0.4, 0.9) | 0.022 |
| III | 1.8 (1.5, 2.1) | <0.001 | 1.4 (1.0, 2.1) | 0.044 |
| IV | 2.8 (2.1, 3.8) | <0.001 | 2.6 (1.9, 3.7) | <0.001 |
| Transfusion, yes | 0.6 (0.5, 0.8) | <0.001 | 0.9 (0.7, 1.2) | 0.343 |
| Blood loss, >400 ml | 1.4 (1.2, 1.6) | <0.001 | 1.2 (1.0, 1.5) | 0.059 |
| Margin, R1 | 1.7 (1.4, 2.2) | <0.001 | 1.7 (1.3, 2.1) | <0.001 |
| Anatomy resection | 0.8 (0.7, 0.9) | 0.002 | 0.9 (0.7, 1.1) | 0.277 |
| Postoperative TACE | 1.8 (1.6, 2.2) | <0.001 | 1.8 (1.5, 2.2) | <0.001 |
| Tumor type | ||||
| cHCC-CC | Ref | Ref | ||
| HCC | 1.0 (0.8, 1.2) | 0.799 | 0.9 (0.6, 1.2) | 0.397 |
| ICC | 2.3 (1.8, 3.1) | <0.001 | 3.5 (2.5, 4.9) | <0.001 |
Abbreviation: cHCC-CC: Combined hepatocellular carcinoma and cholangiocarcinoma; HCC: hepatocellular carcinoma; ICC: intrahepatic cholangiocarcinoma; HR: hazard ratio; CI: confidence interval; Ref: reference; ALB: albumin; AJCC: American Joint Committee on Cancer; TACE: transhepatic arterial chemotherapy and embolization; HR: hazard ratio; CI: confidence interval; ref: reference.